The latest price target for Microbot Medical (NASDAQ:MBOT) was reported by HC Wainwright & Co. on June 3, 2024. The analyst firm set a price target for $7.00 expecting MBOT to rise to within 12 months (a possible 586.27% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Microbot Medical (NASDAQ:MBOT) was provided by HC Wainwright & Co., and Microbot Medical reiterated their buy rating.

There is no last upgrade for Microbot Medical

There is no last downgrade for Microbot Medical.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Microbot Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Microbot Medical was filed on June 3, 2024 so you should expect the next rating to be made available sometime around June 3, 2025.

While ratings are subjective and will change, the latest Microbot Medical (MBOT) rating was a reiterated with a price target of $7.00 to $7.00. The current price Microbot Medical (MBOT) is trading at is $1.02, which is out of the analyst’s predicted range.